Radioisotope-labelled lipiodol has been used in the therapy of liver cancer. Recently a lipiodol solution of 188 Re-labelled diaminedithiol (DD) has been reported to show a high uptake in the liver cancer. We synthesized long-chain alkyl DD derivatives to improve their uptake and retention in tissue. As the length of the alkyl chain increased, tissue uptake and retention also increased due to hydrophobic interaction with lipiodol. Among the synthesized compounds, the lipiodol solution of 188 Re-HDD, the DD derivative with the longest side chain (C 16 ), is a promising agent for therapy of liver cancer. (# 2002 Lippincott Williams & Wilkins) 
Introduction
The blood supply of liver cancer is mainly from the hepatic artery, while that of normal hepatic cells is mainly from the portal vein. Consequently, embolic agents accumulate in liver cancer if they are administered through the hepatic artery.
Lipiodol is an iodinated and esterified lipid of poppy seed oil that has been used as a contrast agent for the detection of liver cancer. When injected through the hepatic artery it accumulates in the liver cancer because of its high viscosity. This property of lipiodol has encouraged many researchers to use it as a radioisotope carrier. Other carriers such as microspheres can also be used. However, lipiodol is the most effective and convenient carrier because of its excellent targeting ability as well as its capacity to be accurately monitored by X-ray.
There have been many attempts to label lipiodol with therapeutic radioisotopes, including 131 I, 90 Y, 186 Re and 188 Re [1±8] . 131 I-labelled lipiodol is commercially available and is currently used in many countries. However, its high cost and high external radiation dose due to its high energy gamma radiation limits its general use. Among the metallic beta emitters, 188 Re became the most important candidate for labelling lipiodol because of its convenience and economy. Early attempts to label lipiodol with 188 Re were not very successful, since 188 Re is obtained as an aqueous solution and lipiodol is available as an oil. Direct chemical reaction is precluded because they are not miscible. If a bichelating agent were to be linked with lipiodol in order to facilitate labelling with 188 Re, the chemical properties of the resulting conjugate would be changed. In addition, its chemistry would be difficult to characterize since lipiodol is not composed of a single substance.
A new method to overcome these problems has been reported [9] . Instead of labelling lipiodol itself, 2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (DD) is labelled. DD, which is an N 2 S 2 or diaminedithiol compound, is known to make a stable lipophilic chelate with rhenium or technetium. Labelling of DD can be performed in an aqueous solution. The resulting lipophilic chelate can be extracted with lipiodol. It is proposed that 188 Re-DD will stay in the lipiodol phase because of its high lipophilicity both in vitro and in vivo. Our previous results have indicated that a lipiodol solution of 188 Re-DD is stable and stays in the lipiodol phase in vitro. In addition, it showed high accumulation in liver cancer when injected through the hepatic artery; however, its retention in liver cancer was not satisfactory.
In order to improve the retention of 188 Re in liver cancer, we synthesized long-chain alkyl DD derivatives ( Fig. 1 ) and investigated their radiochemical and biological properties.
Methods
Reagents used in the syntheses were purchased from the Sigma-Aldrich Company or from the Guerbet Company and used without further purification unless otherwise indicated. Analytical thin layer chromatography (TLC) was performed on Kieselgel 60F254 (0.25 mm, Merck), and the spots were detected with an ethanolic panisaldehyde solution and/or an ultraviolet light. The chemical structures of the synthesized compounds were confirmed by nuclear magnetic resonance (NMR) spectroscopy (Varian 300-MHz Gemini 300 FT-NMR spectrometer). The samples prepared for NMR analysis were dissolved either in CDCl 3 with TMS as an internal reference or in D 2 O purchased from the Sigma-Aldrich Company. The 188 W/ 188 Re generator was purchased from the Oak Ridge National Laboratory and the ITLC-SG was purchased from the Gelman Company. 4-Octyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (ODD) Activated zinc powder (8 mg, 0.12 mmol) and 2 M hydrogen chloride solution (1 ml) were added to a solution of 5-octyl-3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodecane (21 mg, 0.06 mmol) in ethanol (3 ml). After stirring for 5 h, the reaction mixture was filtered through Celite 545 and the filtrate was evaporated under reduced pressure. The residue was dissolved in water and extracted with chloroform (3 ml63). The organic layer was washed with saturated sodium chloride solution (1 ml), and dried over anhydrous sodium sulphate. To this solution, 4 M hydrogen chloride solution in 1,4-dioxane (0.5 ml) was added. The solution was evaporated under reduced 238 Lee et al. 4-Dodecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (DDD) Activated zinc powder (166 mg, 2.54 mmol) and 2 M hydrogen chloride solution (6 ml) were added to a solution of 5-dodecyl-3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodecane (515 mg, 1.27 mmol) in ethanol (10 ml). After stirring for 5 h, the reaction mixture was filtered through Celite 545, and the filtrate was evaporated under reduced pressure. The residue was dissolved in water and the aqueous layer was extracted with chloroform (5 ml63). The organic layer was washed with saturated sodium chloride solution (5 ml) and dried over anhydrous sodium sulphate. To this solution, 4 M hydrogen chloride solution in 1,4-dioxane (2 ml) was added. The solution was evaporated under reduced pressure, and dried in vacuo to give DDD (149.7 mg, 0.37 mmol, 29%) as a white gel. TLC (silica gel/ diethylether:n-hexane:n-propylamine = 7:3:1), R f = 0.1; 4-Hexadecyl-2,2,9,9-tetramethyl-4,7-diaza-1,10-decanedithiol (HDD) Activated zinc powder (40 mg, 0.62 mmol) and 2 M hydrogen chloride solution (2 ml) were added to a solution of 5-hexadecyl-3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodecane (141 mg, 0.31 mmol) in ethanol (5 ml). After stirring for 5 h, the reaction mixture was filtered through Celite 545, and the filtrate was condensed under reduced pressure. The residue was dissolved in water and the aqueous layer was extracted with chloroform (5 ml63). The organic layer was washed with saturated sodium chloride solution (5 ml) and dried over anhydrous sodium sulphate. To this solution, 4 M hydrogen chloride solution in 1,4-dioxane (2 ml) was added. The solution was evaporated under reduced pressure, and dried in vacuo to give HDD (123 mg, 0.27 mmol, 86%) as a white gel. TLC (silica gel/diethylether:nhexane:n-propylamine = 7:3:1), R f = 0. (Fig. 2) . The labelling efficiency was checked using ITLC as the stationary phase and ethyl acetate, normal saline or acetone as the mobile phase. The Rf values of the 188 Re-DD derivatives were between 0.7 and 1.0 using ITLC/ ethyl acetate, 1.0 using ITLC/acetone and 0.0 using ITLC/normal saline. The R f values of 188 Re-perrhenate were 0.8 using ITLC/ethyl acetate and 1.0 using ITLC/ normal saline and ITLC/acetone. The Rf values of 188 Retartaric acid and 188 Re-colloid using ITLC/normal saline were 1.0 and 0.0, respectively. Lipiodol (3 ml) was added to the vial and vigorously shaken to extract the labelled 188 Re-DD into the lipiodol phase. The vial was then centrifuged for 10 min at 3000 r.p.m. to separate the water and the lipiodol phase. The lower lipiodol phase containing the lipophilic 188 Re-DD derivative was carefully collected using a syringe with a long needle (Fig. 2) .
The stability of the 188 Re-DD derivatives in lipiodol at room temperature was checked for 48 h. Its stability in human serum was also checked at 378C for 48 h. The same chromatography conditions as described were used to analyse the radioactive components during the stability test.
Biodistribution
Lipiodol solutions of the compounds (0.03 ml, 0.74 MBq) were injected through the tail vein of ICR mice. Mice were sacrificed by cervical dislocation after 10 min, 30 min, 1 h, 3 h and 24 h. The weights and radioactivity of the organs were measured and the percentages of injected dose per organ weight (% ID×g 71 ) were calculated. 
Results

Synthesis
DD was synthesized using a previously reported method [9±11] . Alkylation of the 3,3,10,10-tetramethyl-1,2-dithia-5,8-diazacyclodecane was catalysed by potassium carbonate in acetonitrile. The alkylated compounds were purified using preparative TLC before reduction. Zinc powder in 2 M hydrogen chloride was used as a reducing agent instead of lithium aluminium hydride as reported previously.
Radiochemistry
The labelling efficiencies of alkyl DD derivatives were between 60 and 80%. Final yields were between 50 and 70%. The radiochemical purities of the final preparations were higher than 97%. The in vitro stability was higher than 85% after 48 h. Although the R f values of 188 Re-perrhenate and 188 Realkyl DD were similar when analysed using ITLC/ethyl acetate, only 188 Re-alkyl DD could be extracted with lipiodol.
188 Re-perrhenate always stayed in the aqueous phase.
Biodistribution
The major uptake site of the lipiodol solution of 188 Realkyl DD was the lung, which represents uptake by embolic mechanism (Table 1) . Uptake and retention in the lung increased as the length of alkyl side chain increased (Table 1 and Fig. 3 ). The intestinal activity is thought to be the result of bile excretion. As the alkyl chain became longer, the bile excretion decreased ( Table  2) .
Discussion
188 Re-DD has high lipophilicity and initial uptake in liver cancer is high. However, retention in the tumour is low [9] . This can be explained by assuming that there is an equilibrium between the neutral lipophilic form and the positively charged water-soluble form. In a closed system such as an in vitro system, most 188 Re-DD exists in a lipophilic form and stays in lipiodol. However, in an open system such as an in vivo system, a small amount of the water-soluble form is continuously washed out by flowing body fluid (Fig. 4) .
Our aim was to increase the retention in the lipiodol phase by increasing the hydrophobic interaction between lipiodol and the long alkyl chain (Fig. 5) . With a long alkyl chain even a positively charged form would persist in the lipiodol phase. Our results clearly show high retention of 188 Re-alkyl DD, especially 188 Re-HDD. We investigated the lung uptake after injecting the agents through the tail vein of mice instead of using a rat hepatoma model. The mechanism of lung uptake of lipiodol is due to capillary blocking, similar to microspheres or macroaggregated albumin [14] . Administration of lipiodol through the hepatic artery in a rat model 240 Lee et al.
Nuclear Medicine Communications (2002) 23 Fig. 3 Radioactivity changes in the lung after injection of lipiodol solution of 188 Re-alkyl DD into mice through the tail vein. Fig. 4 Re-DD has a neutral charge [10] . However, it exists in equilibrium with its positively charged form in solution. Positively charged Re-DD is continuously washed out by body fluids flowing around the tissue. of liver cancer is technically demanding and the results are highly variable [9] .
The stability of 188 Re-alkyl DD was high in our experiments using low radioactivity (537 MBq×ml 71 ). However, significant radiolysis might occur in clinical practice, where a higher radioactivity would be used for therapy. Oxygen and light are the most detrimental factors to the stability of the agent. To address this problem, addition of some lipophilic antioxidant to the lipiodol solution might be useful, and a protocol that minimizes exposure to oxygen and light might also be helpful.
Another problem is the fact that lipiodol can dissolve and destroy some plastics used in tubing, syringes, threeway cocks, and so on. Generally, polypropylene is more resistant than rubber or polystyrene. The effect often Re-HDD is a promising new agent that is easy to label due to a simplified procedure, is stable in vitro and in vivo, and is retained long enough in the liver cancer for use in therapy.
Conclusion
We synthesized alkyl DD derivatives (ODD, DDD and HDD) and established the optimal condition for labelling with 188 Re and their lipiodol solutions. We showed that a lipiodol solution of Table 2 . Ratios (mean+SD) between intestine uptake and lung uptake. 
DD
